59 related articles for article (PubMed ID: 12889482)
21. Indinavir--study highlights importance of CD4+ counts over viral load.
TreatmentUpdate; 1998 Nov; 10(9):2-3. PubMed ID: 11365923
[TBL] [Abstract][Full Text] [Related]
22. Choosing the best initial therapy for HIV-1 infection.
Clumeck N
N Engl J Med; 1999 Dec; 341(25):1925-6. PubMed ID: 10601514
[No Abstract] [Full Text] [Related]
23. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
24. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients].
Salmon-Céron D; Deleuze J; Coste J; Guerin C; Ginsburg C; Blanche P; Finkielsztejn L; Pecqueux L; Chaput S; Gorin I; Sicard D
Ann Med Interne (Paris); 2000 Jun; 151(4):297-302. PubMed ID: 10922958
[TBL] [Abstract][Full Text] [Related]
25. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
26. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
27. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
Autar RS; Boyd MA; Wit FW; Ruxrungthams K; Sankote J; Lange J; Cooper DA; Phanuphak P; Burger DM; Reiss P
Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866
[TBL] [Abstract][Full Text] [Related]
28. New study shows efavirenz effective with d4T and 3TC.
AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404
[TBL] [Abstract][Full Text] [Related]
29. Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Saah AJ; Haas DW; DiNubile MJ; Chen J; Holder DJ; Rhodes RR; Shivaprakash M; Bakshi KK; Danovich RM; Graham DJ; Condra JH
J Infect Dis; 2003 Apr; 187(7):1157-62. PubMed ID: 12660932
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression.
Holmberg SD; Hamburger ME; Moorman AC; Wood KC; Palella FJ;
Clin Infect Dis; 2003 Sep; 37(5):702-7. PubMed ID: 12942404
[TBL] [Abstract][Full Text] [Related]
32. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
33. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
[No Abstract] [Full Text] [Related]
34. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
[TBL] [Abstract][Full Text] [Related]
35. Ritonavir and indinavir one year later.
TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
[No Abstract] [Full Text] [Related]
36. Data in from first head-to-head protease inhibitor.
AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
[No Abstract] [Full Text] [Related]
37. Amping amprenavir with ritonavir.
TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
[No Abstract] [Full Text] [Related]
38. Risk factors for ritonavir intolerance and outcome after change to indinavir.
Casado JL; Perez-Elías MJ; Antela A; Martí-Belda P; de Lucas S; Muñoz V; Guerrero A
AIDS; 1998 Feb; 12(3):335-6. PubMed ID: 9580044
[No Abstract] [Full Text] [Related]
39. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
Salzberger B; Rockstroh J; Wieland U; Franzen C; Schwenk A; Jütte A; Hegener P; Cornely O; Mörchen C; Gaensicke T; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Nov; 4(11):449-55. PubMed ID: 10585299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
